Evaluation Emerging Targets in the Management of Schizophrenia: The Potential of TAAR1 Agonists Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Leslie Citrome, MD, MPH 5 4 3 2 1 Amber Hoberg, NP 5 4 3 2 1 Rakesh Jain, MD, MPH 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Describe the limitations and barriers associated with the use of antipsychotics for schizophrenia whose MOA centers on dopamine D2 binding, including a discussion surrounding antipsychotic nomenclature 5 4 3 2 1 Evaluate the mechanism of action and safety/efficacy data associated with TAAR1 agonism in the management of schizophrenia 5 4 3 2 1 Summarize the potential clinical implications for TAAR1 agonists in the management of schizophrenia and how to identify/educate patients who might benefit from these novel therapies 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with Schizophrenia on a monthly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage Schizophrenia. Excellent Very Good Good Fair Poor Based on my participation in this activity, I anticipate I will more often: Assess the limitations of antipsychotics for schizophrenia whose mechanism of action centers on dopamine D2 binding Assess the impact of negative symptoms in patients with schizophrenia Assess the impact of cognitive dysfunction in patients with schizophrenia Track weight change in patients with schizophrenia Remain apprised of the latest advances in schizophrenia research contributing to emerging treatment options with improved safety and efficacy profiles Assess the potential clinical considerations associated with TAAR1 agonists in patients with schizophrenia Discuss the potential benefit of TAAR1 agonists with patients for the management of schizophrenia Implement TAAR1 agonists into routine clinical practice, when available, for the treatment of schizophrenia Other (please specify): Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Previous
